BioNTech (NASDAQ:BNTX) Stock Price Expected to Rise, Morgan Stanley Analyst Says

BioNTech (NASDAQ:BNTX) had its target price raised by stock analysts at Morgan Stanley from $125.00 to $126.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 35.13% from the stock’s current price.

Several other equities analysts also recently commented on BNTX. Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 price target on shares of BioNTech in a report on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. BMO Capital Markets cut their price target on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. Citigroup cut their price target on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Finally, HC Wainwright cut their price target on shares of BioNTech from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $133.13.

BioNTech Price Performance

Shares of BioNTech stock traded up $1.27 during trading hours on Friday, reaching $93.25. The company’s stock had a trading volume of 63,746 shares, compared to its average volume of 1,108,985. The firm has a 50 day moving average price of $99.18 and a 200-day moving average price of $101.04. BioNTech has a one year low of $79.52 and a one year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. The stock has a market cap of $23.43 billion, a P/E ratio of -17.78 and a beta of 1.58.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The business had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. On average, analysts predict that BioNTech will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

Large investors have recently modified their holdings of the company. Larson Financial Group LLC boosted its holdings in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the period. EFG International AG bought a new position in shares of BioNTech during the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after purchasing an additional 260 shares in the last quarter. Financial Consulate Inc. bought a new position in shares of BioNTech during the third quarter valued at approximately $36,000. Finally, Huntington National Bank boosted its stake in shares of BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.